Evidence map›Paper›PMID 26243280›Full record

ArticleMalaria journal2015

Improvement of culture conditions for long-term in vitro culture of Plasmodium vivax.

Wanlapa Roobsoong, Chayada S Tharinjaroen, Nattawan Rachaphaew, Porpimon Chobson, Louis Schofield, Liwang Cui, John H Adams, Jetsumon Sattabongkot

Abstract read
In one paragraph

Article in Malaria journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Complement receptor 1 is the human erythrocyte receptor forProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
  4. Biology and epidemiology ofParasite epidemiology and control · 2023
    Review
  5. The direct binding ofProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Article
  7. Review
  8. The challenges ofFrontiers in immunology · 2022
    Article
  9. Article
  10. Review
  11. Infectivity of Symptomatic Malaria Patients toFrontiers in cellular and infection microbiology · 2021
    Article
  12. Home Sweet Home:Frontiers in cellular and infection microbiology · 2021
    Review
  13. Identification of the RecombinantFrontiers in cell and developmental biology · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. A Way Forward for Culturing Plasmodium vivax.Trends in parasitology · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wanlapa RoobsoongMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. wanlapa.ros@mahidol.edu.
Chayada S TharinjaroenDivision of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. chayada.si@cmu.ac.th.
Nattawan RachaphaewMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. nattawan.rac@mahidol.ac.th.
Porpimon ChobsonMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. ppchobson@gmail.com.
Louis SchofieldDepartment of Infectious Diseases, Walter and Elisa Hall Institute of Medical Research, Melbourne, Australia. schofield@wehi.edu.au.
Liwang CuiDepartment of Entomology, The Pennsylvania State University, University park, PA, USA. luc2@psu.edu.
John H AdamsDepartment of Global Health, University of South Florida, Tampa, USA. usfmalaria@gmail.com.
Jetsumon SattabongkotMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. jetsumon.pra@mahidol.edu.

Funding

Immunological characterization of the P. vivax DBPR01AI064478 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI ADAMS, JOHN H · 2006 to 2023
$9.6M
Vivax Malaria culture technique and genetic diversity in ThailandD43TW006571 · FIC · PENNSYLVANIA STATE UNIVERSITY-UNIV PARK · PI CUI, LIWANG · 2004 to 2018
$1.9M
FIC NIH HHS D43 TW006571NIAID NIH HHS R01 AI064478
6 · The paper itself

Abstract

backgroundThe study of the biology, transmission and pathogenesis of Plasmodium vivax is hindered due to the lack of a robustly propagating, continuous culture of this parasite. The current culture system for P. vivax parasites still suffered from consistency and difficulties in long-term maintenance of parasites in culture and for providing sufficient biological materials for studying parasite biology. Therefore, further improvement of culture conditions for P. vivax is needed.

methodsClinical samples were collected from patients diagnosed with P. vivax in western Thailand. Leukocyte-depleted P. vivax infected blood samples were cultured in a modified McCoy's 5A medium at 5% haematocrit under hypoxic condition (5% O2, 5% CO2, and 90% N2). Reticulocytes purified from adult peripheral blood were added daily to maintain 4% reticulocytes. Parasites were detected by microscopic examination of Giemsa-stained smears and molecular methods.

resultsThe effects of culture variables were first analysed in order to improve the culture conditions for P. vivax. Through analysis of the sources of host reticulocytes and nutrients of culture medium, the culture conditions better supporting in vitro growth and maturation of the parasites were identified. Using this system, three of 30 isolates could be maintained in vitro for over 26 months albeit parasite density is low.

conclusionsBased on the analysis of different culture variables, an improved and feasible protocol for continuous culture of P. vivax was developed.

Indexed as

Plasmodium vivaxCell Culture TechniquesCulture MediaErythrocytesHumansMalaria, VivaxParasite LoadReticulocytesCulture Media

Identifiers

PMID26243280
PMCPMC4524445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.